menu
    • menu

    Company profile for Avacta Therapeutics

    NEW Drugs in Dev: 1
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Avacta is a clinical stage biotechnology company expanding the reach of highly potent cancer therapies with the pre|CISION? platform.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Avacta Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Scale Space, White City Imperial College Campus 58 Wood Lane London
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://avacta.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/avacta/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Avacta Shows AVA6000 Early Efficacy In Salivary Gland Cancer
    Avacta Shows AVA6000 Early Efficacy In Salivary Gland Cancer

    01 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/01/3304013/0/en/avacta-presents-updated-clinical-data-showing-encouraging-early-efficacy-signals-for-ava6000-in-salivary-gland-cancers-at-asco-2026.html

    GLOBENEWSWIRE
    01 Jun 2026
    Share Share
    Unaudited Preliminary Results for Year Ended December 31, 2025
    Unaudited Preliminary Results for Year Ended December 31, 2025

    19 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/19/3297150/0/en/unaudited-preliminary-results-for-the-year-ended-december-31-2025.html

    GLOBENEWSWIRE
    19 May 2026
    Share Share
    Avacta Shows pre|CISION Payload Edge Over Approved ADCs
    Avacta Shows pre|CISION Payload Edge Over Approved ADCs

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3288498/0/en/avacta-presents-new-comparisons-of-pre-cision-payload-release-vs-approved-adcs-and-ava6207-dual-payload-delivery-at-science-day-2026.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    Avacta data at AACR 2026 underline favorable profile of AVA6103
    Avacta data at AACR 2026 underline favorable profile of AVA6103

    21 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/21/3278250/0/en/avacta-data-at-aacr-2026-underline-favorable-profile-of-ava6103-and-advantages-of-pre-cision-delivery-platform.html

    GLOBENEWSWIRE
    21 Apr 2026
    Share Share
    Avacta CEO Christina Coughlin Named In Vivo 2026 Rising Leader
    Avacta CEO Christina Coughlin Named In Vivo 2026 Rising Leader

    14 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/14/3273220/0/en/Avacta-CEO-Christina-Coughlin-Named-as-One-of-In-Vivo-s-2026-Rising-Leaders.html

    GLOBENEWSWIRE
    14 Apr 2026
    Share Share
    Avacta Treats First Patient in Phase 1 FOCUS-01 FAP-Exd Trial
    Avacta Treats First Patient in Phase 1 FOCUS-01 FAP-Exd Trial

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3265176/0/en/Avacta-announces-first-patient-treated-in-Phase-1-FOCUS-01-trial-of-FAP-Exd-AVA6103-a-sustained-release-pre-CISION-exatecan-peptide-drug-conjugate.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

    Details:

    AVA6103 is a peptide-drug conjugate drug, which is currently being evaluated in Phase I clinical studies for the treatment of vulvar adenocarcinoma.


    Lead Product(s): AVA6103

    Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Peptide-drug Conjugate

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 06, 2026

    blank

    01

    Avacta Therapeutics

    United Kingdom
    arrow
    PEGS Boston Summit
    Not Confirmed

    Avacta Therapeutics

    United Kingdom
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AVA6103

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

    Details : AVA6103 is a peptide-drug conjugate drug, which is currently being evaluated in Phase I clinical studies for the treatment of vulvar adenocarcinoma.

    Product Name : Undisclosed

    Product Type : Peptide-drug Conjugate

    Upfront Cash : Inapplicable

    March 06, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search